Global Deferiprone Market By Formulation (Tablet, Oral Solution And Capsules), By Indication (Transfusional Iron Overload And Ntdt Caused Iron Overload), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2031

Market.us announces the publication of its most recently generated research report titled, “Deferiprone Market by Formulation (Tablet, Oral Solution and Capsules), by Indication (Transfusional Iron Overload and NTDT Caused Iron Overload), and by Region – Global Forecast to 2031.”, Which offers a holistic view of the Global Deferiprone Market through systematic segmentation that covers every aspect of the target market.

The Deferiprone market was valued at USD 36.0 Mn in 2022 and is expected to reach USD 39.3 Mn by 2032 at a CAGR of 0.9%.

Deferiprone is an iron chelator indicated for the treatment of patients with transfusional iron overload caused due to thalassemia syndromes, particularly when the current chelation therapy is inadequate. Chelation therapy is used to remove the build-up of toxic metals from the body, such as iron, lead, mercury, and arsenic, to prevent patients from getting severe thalassemia symptoms. Deferiprone (tradename Ferriprox), is an FDA-approved drug, majorly used to treat transfusion-dependent thalassemia and other related disorders.

Patients with thalassemia can get a build-up of iron in their bodies, either from the disease or from recurrent blood transfusions. When the body is under a primary iron overload condition or a secondary condition, caused due to lack of iron excretion mechanism, a massive accumulation of possibly toxic substances is experienced, which may lead to iron-induced early death. It is abundantly available, and evidence supports its use in the treatment of chronic iron overload. The drug is also associated with several adverse effects, including agranulocytosis, neutropenia, and gastrointestinal symptoms such as nausea, vomiting, abdominal pain, etc.

The rising prevalence of the life-threatening disease – thalassemia among the population is expected to propel the growth of the global deferiprone market, thus growing incidence and prevalence of the disease are estimated to drive consumption of Deferiprone.

Furthermore, also, development and focus on the provision and access to the populace in developing countries are likely to have a positive impact on the global deferiprone market.

Global Deferiprone Market Revenue (US$ Mn), 2018–2028 

However, Deferiprone is considered genotoxic, carcinogenic, as well as teratogenic. The drug is only recommended when chelation therapy in patients is inadequate. The drug can cause side effects such as nausea, vomiting, stomach/ abdominal pain, joint pain, zinc deficiency, and hypersensitivity in patients; this might hamper the growth of the deferiprone market. Nonetheless, continuous R&D activities towards the use of deferiprone for the treatment of other rare disorders are also expected to increase further adoption of the drug which is anticipated to boost market growth globally.

The global Deferiprone market is segmented on the basis of formulation, indication, and region. On the basis of formulation, the market is segmented into a tablet, oral solutions, and capsules. The tablet segment accounts for the majority share in the global deferiprone market, while the oral solution is expected to register the highest growth rate over the forecast period. On the basis of indications, the market is segmented into Transfusional iron overload, and NTDT caused iron overload, and Transfusional iron overload accounts for a majority share in the global deferiprone market.

Globally, hemochromatosis is on the rise. This is driving the growth of the deferiprone industry. According to the American Diabetes Association website hereditary hemochromatosis, which affects approximately 1 in every 200 to 300 westerners, is the most common single-gene disorder. Moreover, the rising prevalence of transfusion-dependent thalassemia among the population is significantly expected to propel the demand for deferiprone. According to the 2008 World Health Organization bulletin, 1.1% of couples are at risk of having children with hemoglobin disorders and 2.7 percent of all conceptions have this condition.

The deferiprone market is expected to be constrained by adverse reactions like chromaturia and nausea. The deferiprone market is expected to grow due to increased funding from government and private agencies and healthcare initiatives. According to the article in PLOS One Journal 2017, the UAE government launched a nationwide campaign to support premarital screening. Premarital screening is mandatory in UAE for married couples. It provides information about the risks of having a child with thalassemia.

Global Deferiprone Market Attractiveness Analysis by Indication, 2012–2018

On the basis of region, the market is segmented into the United States, China, Europe, Japan, Southeast Asia, India, and the rest of the world. The US accounts for the majority share in the global deferiprone market followed by Europe, owing to increasing government spending on healthcare in this region. Asia Pacific region, Japan, and the rest of the world are expected to register stable growth over the forecast period.

The research report on the global deferiprone market includes profiles of some of the major companies such as Cipla Limited, Apotex Inc., Swedish Orphan Biovitrum AB (publ), Genepharm S.A., Lipomed AG, Ambrosia Remedies (P) Ltd., and Focus Pharmaceuticals Limited.

Due to the growing concern about thalassemia, there is a growing demand for deferiprone. Market growth is expected to be driven by rising demand from the pharmaceutical and medical industries. The increasing clinical use of the medication in treating systemic iron overload is responsible for the market growth. Market growth will be driven by research and development activities related to the medication. The product demand is expected to be driven by the pharmaceutical industry and the adoption of personalized medicine within the population.

Key Market Segments

Formulation

• Tablet
• Oral solution
• Capsules

Indications

• Transfusional iron overload
• NTDT caused an iron overload

Key Market Players included in the report:

• Cipla Limited
• Apotex Inc.
• Swedish Orphan Biovitrum AB (publ)
• Genepharm S.A.
• Lipomed AG
• Ambrosia Remedies (P) Ltd.
• Focus Pharmaceuticals Limited

For the Deferiprone Market research study, the following years have been considered to estimate the market size: